Clinical Trial: Oral Budesonide in Subjects with EoE
ENROLLMENT IS CURRENTLY CLOSED
Purpose: This Phase II study is comparing oral budesonide (OBS) to placebo to demonstrate that OBS improves dysphagia symptoms and induces a histologic response (in esophageal biopsies) over a 16 week course of therapy.
Participants: Patients with eosinophilic esophagitis (EoE) between 12 and 25 years old.
Procedures (methods): Patients will undergo an upper endoscopy with esophageal biopsies, complete a daily diary regarding dsyphagia symptoms, and take the study drug daily.
Sponsor: Meritage Pharma, Inc